Acta Clin Belg
-
Sulfonylurea compounds are commonly used to treat type 2 diabetes mellitus. The case of an old alcoholic addicted diabetic patient treated with gliquidone developing recurrent and prolonged hypoglycaemias refractory to dextrose administration is related. According to the emergency literature, the use of octreotide in sulfonyurea-induced hypoglycaemia refractory to dextrose administration is related to overdoses of SUA. Use of octreotide with our patient allowed stabilization of the glycaemia.
-
Multicenter Study
90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Severe sepsis is the major cause of mortality in intensive care units (ICUs). The BOOST study (= B (Belgian) OO (Open Label) ST (Study)) is a Belgian open-label trial designed to pragmatically assess the safety and efficacy of Drotrecogin Alfa (activated) (DAA), the only registered treatment in this indication with favourable ratio benefit/risk. ⋯ Despite a higher severity of illness at baseline, this phase IV open-label long-term study in Belgian ICUs shows consistent results with previous studies with DAA. Importantly, most of the surviving patients at day 90 were staying at home.